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Objective. We studied the effect of the angiotensin II type 1
(AT1)-receptor antagonist candesartan on infarct size resulting
from regional myocardial ischemia in pigs.
Background. The effects of AT1-receptor blockade on infarct
size in different species remain controversial and its potential
cardioprotective mechanisms are still unclear. In pigs, infarct
development closely resembles that observed in humans.
Methods. A total of 62 enflurane-anesthetized pigs underwent a
protocol of 90-min low-flow ischemia and 120-min reperfusion.
Systemic hemodynamics (micromanometer), regional myocardial
function (sonomicrometry), regional myocardial blood flow (mi-
crospheres) and infarct size (TTC [triphenyl tetrazolium
chloride]-staining) were determined.
Results. Left ventricular peak pressure decreased with cande-
sartan (1 mg/kg i.v.) from 97 6 2 standard error of the mean
(SEM) to 86 6 5 mm Hg and was then readjusted by aortic
banding. In placebo pigs (n 5 9), infarct size was 21.8 6 4.8% of
the area at risk. Candesartan (n 5 7) reduced infarct size to 9.7 6
2.5% (p < 0.05). Pretreatment with the AT2-receptor antagonist
PD123319 (3 mg/kg/min intracoronarily [i.c.]; n 5 8), the brady-
kinin B2-receptor antagonist HOE140 (0.01 mg/kg/min i.c.; n 5 8)
or the cyclooxygenase inhibitor indomethacin (10 mg/kg i.v.; n 5
8) per se did not affect infarct size but did abolish the reduction of
infarct size achieved by candesartan (PD123319 1 candesartan
(n 5 7): 23.2 6 4.7%; HOE140 1 candesartan (n 5 7): 18.2 6
4.0%; indomethacin 1 candesartan (n 5 8): 21.1 6 5.2%).
Hemodynamics, regional myocardial blood flow during ischemia
and the area at risk were comparable among all groups of pigs.
Conclusions. Reduction of infarct size by the AT1-receptor
antagonist candesartan in pigs involves angiotensin II type 2
receptor (AT2) activation, bradykinin and prostaglandins.
(J Am Coll Cardiol 1998;32:1787–96)
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The cardiovascular effects of angiotensin II have been largely
attributed to activation of the angiotensin II type 1 (AT1)
receptor (1). Indeed, angiotensin II is locally formed in isch-
emic dog hearts (2), and AT1-receptor blockade increases
coronary blood flow during ischemia in dogs (3), improves
functional and metabolic recovery after myocardial ischemia in
rats (4,5), reduces ischemia-related arrhythmias in rats (6,7)
and guinea pigs (8), and finally attenuates ventricular dilata-
tion after myocardial infarction in rats (6,9).
The AT1-receptor antagonist losartan (DuP753) reduced
infarct size in pigs (10), but not in rats (11–13), rabbits (14–16)
and dogs (17). The AT1-receptor antagonist candesartan cilex-
etil (TCV116), the prodrug of candesartan, reduced creatine
kinase release following 30 min of global ischemia in isolated
rat hearts (5). Because infarct size studies in large animals with
candesartan are lacking and the potential mechanisms involved
in such cardioprotection are unclear, we studied the effect of
the AT1-receptor antagonist candesartan on infarct size result-
ing from severe regional myocardial ischemia in enflurane-
anesthetized pigs. Studies were performed in pigs, as in this
species coronary anatomy (18), the extent of collateral flow
(19) and time course of infarct development most closely
resemble that observed in humans (20).
Blockade of the AT1-receptor increases the angiotensin II
concentration (21), which may then activate the angiotensin II
type 2 (AT2)-receptor (7,9). The AT1-receptor activation, in
turn, increases the formation of local kinins in isolated dog
coronary arteries (22). Left ventricular (LV) dilatation follow-
ing myocardial infarction in rats was attenuated by AT1-
receptor blockade (9); this protective effect was, however,
abolished by blockade of either the AT1-receptor or the
bradykinin B2-receptor. Therefore, a kinin-mediated mecha-
nism secondary to activation of the AT2-receptor may contrib-
ute to the cardioprotection achieved by AT2-receptor block-
ade. Consequently, we tested in subsequent steps of the
experimental protocol the effect of candesartan on infarct
size after pretreatment with the AT2-receptor antagonist
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PD123319 (23) and with the bradykinin B2-receptor antagonist
HOE140 (24).
Because the beneficial effect of angiotensin-converting-
enzyme (ACE) inhibition on the recovery of stunned myocar-
dium also involves bradykinin and subsequently prostaglandins
(25), we finally used the cyclooxygenase inhibitor indometha-
cin (26) to study the involvement of prostaglandins in the
beneficial effect of candesartan.
Methods
The experimental protocols employed in this study were
approved by the Bioethical Committee of the district of
Du¨sseldorf and they adhere to the guiding principles of the
American Physiological Society.
Experimental model. Sixty-four Go¨ttinger minipigs (20 to
40 kg) of either sex were initially sedated using ketamine
hydrochloride (1 g intramuscularly [i.m.]) and then anesthe-
tized with thiopental (Trapanal, 500 mg intravenously [i.v.]).
Through a midline cervical incision, the trachea was intubated
for connection to a respirator (Dra¨ger, Lu¨beck, Germany)
equipped with an enflurane vaporizer. Anesthesia was then
maintained throughout the study using enflurane (1% to 1.5%)
with an oxygen/nitrous oxide mixture (40%:60%). Through the
cervical incision, both common carotid arteries and internal
jugular veins were isolated. The arteries were cannulated with
polyethylene catheters, one for the measurement of arterial
pressure, the other to supply blood to the extracorporeal
circuit. The jugular veins were cannulated for volume replace-
ment using 0.9% NaCl and for the return of blood to the
animal from the coronary venous line (see below). A left
lateral thoracotomy was performed in the fourth intercostal
space and the pericardium opened. A micromanometer (P7,
Konigsberg Instruments, Pasadena, California) was placed in
the left ventricle through the apex together with a saline-filled
polyethylene catheter (used to calibrate the micromanometer
in situ) and secured with a purse-string suture. Ultrasonic
dimension gauges were implanted in the LV myocardium to
measure the thickness of the anterior and posterior (control)
wall (System 6, Triton Technologies, San Diego, California).
Arterial blood gases were monitored frequently in the initial
stages of the preparation until stable and then periodically
throughout the study (ABL 510 Radiometer, Copenhagen,
Denmark). The proximal left anterior descending (LAD)
coronary artery was dissected over a distance of 1.5 cm, ligated,
cannulated and the distal LAD perfused from an extracorpo-
real circuit.
Prior to coronary cannulation the pigs were anticoagulated
with 20,000 IU sodium heparin; additional doses of 10,000 IU
were given at hourly intervals. The system included a roller
pump, windkessel and two side ports, one for the injection of
radiolabeled microspheres, the other for intracoronary infu-
sion of drugs. Coronary arterial pressure was measured from
the sidearm of a polyethylene “T”-connector (Cole-Parmer,
Chicago, Illinois) used as catheter tip with an external trans-
ducer (DPT-6003, pvb Medizintechnik GmbH, Kirchseeon,
Germany). The large epicardial vein parallel to the LAD was
dissected and cannulated. Coronary venous blood was drained
to an unpressurized reservoir and then returned to a jugular
vein using a second roller pump. Heart rate could be controlled
throughout the study by left atrial pacing (Hugo Sachs Elek-
tronik Type 215/T, Hugstetten, Germany) and LV peak pres-
sure could be adjusted by aortic banding. The completed
preparation was allowed to stabilize for at least 30 min before
control measurements were made.
Under control conditions the arterial perfusion pump was
adjusted so that the minimum coronary arterial pressure did
not fall below 70 mm Hg to avoid an initial hypoperfusion.
Therefore, mean coronary arterial pressure exceeded peak LV
pressure. This preparation retains a dynamic coronary auto-
regulation, demonstrating the lack of excessive anesthetic-
dependent coronary vasodilation (27). Rectal temperature was
monitored and kept between 37 to 38°C by use of a heated
surgical table and drapes.
Regional myocardial function. End-diastole was defined as
the point when LV dP/dt started its rapid upstroke after
crossing the zero-line. Regional end-systole was defined as the
point of maximal wall thickness within 20 ms before peak
negative LV dP/dt. Systolic wall thickening was calculated as
end-systolic wall thickness minus end-diastolic wall thickness
divided by the end-diastolic wall thickness.
Regional myocardial blood flow. Radiolabeled micro-
spheres (15 mm diameter, 141Ce, 114In, 51Cr, 113Sn, 103Ru, 95Nb
or 46Sc; NEN, Du Pont, Boston, Massachusetts) were injected
into the coronary perfusion circuit (1–2 3 105 suspended in 1
ml saline) to determine the regional myocardial blood flow and
its distribution throughout the LAD coronary artery perfusion
bed (model 5912, Gammaszint BF 5300 Packard, Germany).
This procedure for the determination of blood flow has been
validated extensively (28). Blood flow to the tissue at the site of
the ultrasonic crystals is reported, and this piece of tissue was
divided into transmural thirds of approximately equal thick-
ness. In addition, the averaged subendocardial blood flow
(14 6 5 pieces with a weight of 1.00 6 0.36 g) to the entire
LAD-perfused territory was measured and related to myocar-
dial infarct size.
Regional myocardial oxygen consumption. Myocardial ox-
ygen consumption of the LAD-perfused territory was mea-
sured using anaerobically sampled blood drawn simultaneously
from the coronary vein and an artery. Oxygen content was
measured using a co-oximeter (Cavitron/LexO2LexO2-Con-k,
Abbreviations and Acronyms
ACE 5 angiotensin-converting-enzyme
AT1 5 angiotensin II type 1 receptor
AT2 5 angiotensin II type 2 receptor
LAD 5 left anterior descending coronary artery
LV 5 left ventricular
SEM 5 standard error of the mean
TTC 5 triphenyl tetrazolium chloride
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Dr. B.G. Schlag, Bergisch Gladbach, Germany). Oxygen con-
sumption of the anterior myocardial wall was calculated by
multiplying the arterial-coronary venous oxygen difference by
the transmural blood flow at the crystal site, as measured using
the microsphere technique.
Morphology. At the end of each study, the heart was
removed and sectioned from base to apex into five transverse
slices in a plane parallel to the atrioventricular groove. The
tissue slices were immersed in a 0.09 mol/liter sodium phos-
phate buffer (pH 7.4) containing 1.0% triphenyl tetrazolium
chloride (TTC; Sigma, Deisenhofen, Germany) and 8% dex-
tran (mol wt, 77.800) for 20 min at 37°C to identify infarcted
tissue. The amount of infarcted tissue is expressed as a
percentage of the LV area at risk, as determined by the
microspheres technique (29).
Experimental protocols. Four subsequent protocols with
two groups each were performed (Fig. 1). Each observation
period began with the simultaneous withdrawal of pairs of
arterial and coronary venous blood samples (1 ml per sample)
for the measurement of oxygen content. During the blood
sampling, microspheres were injected into the LAD perfusion
system for the measurement of regional myocardial blood flow.
Coronary arterial pressure, systemic hemodynamic and re-
gional myocardial dimension data were continuously recorded
to ensure that parameters were unaffected by the microsphere
injection. Measurements were obtained within 2 min; these
were performed under control conditions, after each drug
administration and at 5 and 90 min following the reduction in
coronary blood flow. Coronary blood flow was decreased with
the roller pump to a level sufficient to reduce regional systolic
wall thickening of the anterior wall by .90%. This adjustment
period lasted approximately 3 min; thereafter, no further
changes in flow were made. This level of hypoperfusion was
maintained for 90 min. Following 90 min of ischemia, the
myocardium was reperfused for 120 min to facilitate the
identification of necrotic tissue. During reperfusion, coronary
inflow was set to maintain a minimum coronary arterial
pressure above 70 mm Hg.
Protocol 1. Group 1: Placebo 1 90-min severe ischemia (n 5
9). In the placebo-group following control measurements, a
40-ml saline solution was infused intravenously (i.v.) over
30 min.
Group 2: Candesartan 1 90-min severe ischemia (n 5 7).
Following control measurements, candesartan [2-ethoxy-1[[29-
(1H-tetrazol-5-yl)biphenyl-4-yl]methy]-1H-benzimidazole-7-
carboxylic acid] at a dose of 1 mg/kg (dissolved in 40 ml saline
solution) was infused i.v. within 30 min. Left ventricular (LV)
peak pressure decreased with candesartan and was adjusted to
predrug values by aortic banding. Measurements were re-
peated 30 min following the administration of candesartan at
matched LV peak pressure, before coronary blood flow was
reduced. In five preliminary experiments, this dose of 1 mg/kg
candesartan blocked the vasoconstriction induced by infusion
of angiotensin II (15 mg/min intracoronarily, i.c.). Prior to
candesartan, mean coronary arterial pressure and LV peak
pressure increased with angiotensin II from 105 6 1 to 126 6
4 mm Hg and from 73 6 3 to 103 6 6 mm Hg, respectively
(both p , 0.05). After treatment with candesartan, mean
coronary arterial pressure (106 6 4 vs. 107 6 4 mm Hg) and
LV peak pressure (70 6 3 vs. 72 6 3 mm Hg) did not change
during infusion of angiotensin II.
Protocol 2. Group 3: PD123319 1 90-min severe ischemia
(n 5 8). Following control measurements, PD123319 (S)-1-
[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(diphenyl-acetyl)-
4,5,6,7-tetrahydro-1H-imidazol[4,5-c]-pyridine-6-carboxylic acid]
was infused at a dose (3 mg/kg/min i.c.) adapted from a
previous report (30). Thirty minutes after the start of the
PD123319 infusion, measurements were repeated, before cor-
onary blood flow was reduced. Infusion of PD123319 was
terminated at the end of ischemia.
Group 4: PD123319 1 candesartan 1 90-min severe ischemia
(n 5 8). Following control measurements, the infusion of
PD123319 (3 mg/kg/min i.c.) was started. Following 30-min
PD123319 infusion, candesartan (1 mg/kg i.v.) was infused.
After a total of 60 min, measurements were repeated, before
coronary blood flow was reduced. One animal of this group
Figure 1. Schematic diagram of the four different experimen-
tal protocols.
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died during ischemia due to irreversible ventricular fibrillation;
data of this animal were excluded from the analysis.
Protocol 3. Group 5: HOE140 1 90-min severe ischemia
(n 5 8). Following control measurements, bradykinin B2-
receptors were blocked by infusion of HOE140 (0.01 mg/kg/
min i.c.). The infusion was started 30 min prior to ischemia and
then maintained until the end of ischemic period. This dose
regimen has previously been demonstrated to abolish the
coronary vasodilation induced by intracoronary bradykinin in
the same porcine preparation (31). Thirty minutes after the
start of the HOE140 infusion, measurements were repeated,
before coronary blood flow was reduced.
Group 6: HOE140 1 candesartan 1 90-min severe ischemia
(n 5 7). Following control measurements, the infusion of
HOE140 (0.01 mg/kg/min i.c.) was started. Following 30-min
HOE140 infusion, candesartan (1 mg/kg i.v.) was infused.
After a total of 60 min, measurements were repeated, before
coronary blood flow was reduced.
Protocol 4. Group 7: Indomethacin 1 90-min severe isch-
emia (n 5 8). Following control measurements, the cyclooxy-
genase was inhibited by infusion of indomethacin (10 mg/kg
i.v.). This dose regimen has previously been demonstrated to
abolish the coronary vasodilation induced by intracoronary
arachidonic acid (25). The infusion of indomethacin was
started 40 min prior to ischemia. Fourty minutes after the start
of the indomethacin infusion, measurements were repeated,
before coronary blood flow was reduced.
Group 8: Indomethacin 1 candesartan 1 90-min severe
ischemia (n 5 9). Following control measurements, the infu-
sion of indomethacin (10 mg/kg i.v.) was started. Following a
40-min indomethacin infusion, candesartan (1 mg/kg i.v.) was
infused. After a total of 70 min, measurements were repeated,
before coronary blood flow was reduced. One animal of this
group died during ischemia due to irreversible ventricular
fibrillation; data of this animal were excluded from the analy-
sis.
Data analysis and statistics. Hemodynamic data were re-
corded on an 8-channel recorder (Gould MK 200A, Cleveland,
Ohio) and stored directly to the hard disk of an AT-type
computer. Hemodynamic and functional parameters were dig-
itized and recorded over a 20-s period during each micro-
sphere injection (approximately 33 consecutive beats over at
least two complete respiratory cycles) using CORDAT II
software (32). Hemodynamic parameters reported are heart
rate, LV peak pressure, LV dP/dtmax and mean coronary
arterial pressure. Regional wall function is expressed as systolic
wall thickening. Calculation of all hemodynamic parameters
was done on a beat-to-beat basis, and data were then averaged.
In addition, regional myocardial blood flow and oxygen con-
sumption were measured.
Statistical analysis was performed using SYSTAT software
(Urbana, Illinois). Data on hemodynamics, wall thickening,
myocardial blood flow and oxygen consumption were com-
pared using a two-way analysis of variance (ANOVA) for
repeated measures, accounting for the different time points
throughout the protocol and the eight groups of pigs. When
significant differences were detected, individual mean values
were compared using LSD post-hoc tests. Area at risk and
infarct size were compared for each protocol separately by the
Student unpaired t test. All data are reported as mean
values 6 standard error of the mean (SEM), and a p value less
than 0.05 was accepted as indicating a significant difference in
mean values. Linear regression analyses between subendocar-
dial blood flow at 5 min ischemia in the LV area at risk and
infarct size (expressed as percentage of the area at risk) were
performed in all groups. Regression lines were compared by
analysis of covariance (ANCOVA).
Results
No significant differences were observed in any measured
parameter among the groups under control conditions. Data
on systemic hemodynamics are summarized in Table 1. Data
on regional myocardial function, blood flow and oxygen con-
sumption are summarized in Table 2. The incidence of arrhyth-
mias was low (peak incidence of 18 6 9 ventricular
extrasystoles/5 min in the placebo group) and not different
among groups.
In all groups of pigs, by decreasing the pump speed,
coronary blood flow was reduced such that mean coronary
arterial pressure was decreased. The LV peak pressure was
decreased at 5 min ischemia in groups 1, 2, 4, 5 and 6. The
LVdP/dtmax was decreased at 5 min ischemia in all groups of
pigs with the exception of group 3. In all groups of pigs, both
systolic wall thickening of the anterior myocardium, subendo-
cardial and transmural myocardial blood flow and regional
myocardial oxygen consumption were decreased at 5 min
ischemia. During the remainder of the 90-min ischemic period,
systemic hemodynamics, anterior systolic wall thickening, re-
gional myocardial blood flow and oxygen consumption did not
change further.
Left ventricular peak pressure decreased with candesartan
from 97 6 2 to 86 6 5 mm Hg and was readjusted before
further measurements. Candesartan had no significant effect
on heart rate, LVdP/dtmax (Table 1), systolic wall thickening of
the anterior myocardium or regional myocardial oxygen con-
sumption (Table 2). Transmural myocardial blood flow in-
creased with candesartan in group 6.
PD123319 alone and in combination with candesartan did
not significantly change systemic hemodynamics, anterior sys-
tolic wall thickening and oxygen consumption (Tables 1 and 2).
Subendocardial and transmural myocardial blood flow tended
to increase (NS) with PD123319.
Both alone and in combination with candesartan, HOE140
did not significantly change systemic hemodynamics, anterior
systolic wall thickening, regional myocardial blood flow and
oxygen consumption (Tables 1 and 2).
Indomethacin increased LV peak pressure and mean cor-
onary arterial pressure, whereas anterior systolic wall thicken-
ing was decreased. Indomethacin alone and in combination
with candesartan did not significantly change regional myocar-
dial blood flow and oxygen consumption (Tables 1 and 2).
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Infarct size. The area at risk in percent of LV mass was
comparable among all groups of pigs (group 1: 46.8 6 3.0%;
group 2: 55.3 6 1.9%; group 3: 47.4 6 2.8%; group 4: 50.9 6
3.1%; group 5: 49.9 6 3.1%; group 6: 44.5 6 2.6%; group 7:
44.1 6 3.2%; group 8: 45.1 6 3.5%).
In placebo pigs, following 90 min of ischemia and 120 min
of reperfusion, infarct size was 21.8 6 4.8% of the area at risk
(Fig. 2). Candesartan significantly reduced infarct size to 9.7 6
2.5% (p , 0.05 vs. placebo) (Fig. 2). Infarct size for any given
subendocardial blood flow was significantly reduced in the
candesartan group (y 5 2210.1z3 1 18.6, n 5 7, r 5 20.83) vs.
placebo group (y 5 2497.4z3 1 44.7, n 5 9, r 5 20.84, p ,
0.05) (Fig. 2).
The AT2-receptor antagonist PD123319 per se did not
affect infarct size (16.8 6 4.0%) (Fig. 3). Pretreatment with
PD123319 abolished the reduction of infarct size by candesar-
tan (23.2 6 4.7%). The relationships between infarct size and
subendocardial blood flow in groups 3 and 4 were superimpos-
able (y 5 2430.0z3 1 36.5, n 5 8, r 5 20.85 vs. y 5
2491.7z3 1 47.0, n 5 7, r 5 20.90) (Fig. 3).
The B2-receptor antagonist HOE140 per se did not affect
infarct size (15.7 6 2.8%) (Fig. 4), but pretreatment with
HOE140 abolished the reduction of infarct size by candesartan
(18.2 6 4.0%). The relationships between infarct size and
subendocardial blood flow in groups 5 and 6 were superimpos-
able (y 5 2328.9z3 1 33.0, n 5 8, r 5 20.86 vs. y 5
2294.9z3 1 33.1, n 5 7, r 5 20.88) (Fig. 4).
The cyclooxygenase inhibitor indomethacin per se did not
affect infarct size (22.5 6 5.5%) (Fig. 5), but pretreatment with
indomethacin abolished the reduction of infarct size by cande-
sartan (21.1 6 5.2%). The relationships between infarct size
and subendocardial blood flow in groups 5 and 6 were super-
imposable (y 5 2370.7z3 1 38.8, n 5 8, r 5 20.81 vs. y 5
2323.1z3 1 34.8, n 5 8, r 5 20.74) (Fig. 5).








HR (min21) 1 103 6 2 105 6 3 105 6 3
2 95 6 5 98 6 5 101 6 5 104 6 7
3 96 6 3 96 6 3 103 6 6 105 6 4
4 94 6 3 95 6 3 96 6 4 100 6 2 110 6 8
5 99 6 3 100 6 3 101 6 3 104 6 2
6 95 6 3 95 6 4 97 6 4 98 6 4 107 6 4
7 102 6 6 103 6 7 104 6 6 116 6 7
8 102 6 4 102 6 3 108 6 4 110 6 4 115 6 7
LVpP (mm Hg) 1 93 6 3 84 6 5* 81 6 4*
2 97 6 2 94 6 3 79 6 3*# 84 6 5*
3 94 6 5 98 6 4 83 6 4 85 6 8
4 100 6 5 103 6 6 101 6 5 86 6 5# 82 6 6*
5 100 6 3 97 6 3 82 6 3*# 82 6 3*
6 98 6 5 100 6 5 93 6 5 81 6 4* 83 6 5*
7 92 6 4 106 6 5* 83 6 4# 89 6 4
8 98 6 4 112 6 6* 105 6 6 91 6 5§ 88 6 5
LVdP/dtmax (mm Hg/s) 1 1319 6 67 919 6 64* 949 6 56*
2 1373 6 95 1244 6 77 883 6 53*# 1083 6 104*
3 1241 6 113 1272 6 102 1017 6 92 1067 6 131
4 1319 6 64 1356 6 73 1274 6 103 994 6 78*# 1074 6 110*
5 1293 6 78 1274 6 110 899 6 41*# 950 6 57*
6 1336 6 73 1337 6 68 1163 6 54 918 6 39*# 947 6 48*
7 1299 6 84 1140 6 81 909 6 42*# 983 6 76*
8 1452 6 98 1274 6 70 1229 6 55* 1024 6 36*# 1038 6 90*
CAP (mm Hg) 1 120 6 2 29 6 2*# 26 6 2*
2 114 6 3 118 6 2 27 6 1*# 25 6 1*
3 116 6 4 119 6 5 27 6 3*# 23 6 3*
4 120 6 5 116 6 2 112 6 4 29 6 2*# 27 6 2*
5 115 6 1 115 6 2 29 6 1*# 28 6 2*
6 113 6 3 111 6 3 112 6 4 27 6 1*# 24 6 1*
7 117 6 3 158 6 8* 29 6 2*# 27 6 2*
8 119 6 4 154 6 9* 129 6 10# 30 6 1*# 28 6 2*
HR, heart rate; LVpP, left ventricular peak pressure; LV dP/dtmax, maximum of the first derivative of left ventricular
pressure; CAP, mean coronary arterial pressure; *p , 0.05 vs. control; #p , 0.05 vs. preceding value; §p , 0.05 vs. drug.
Group 1, placebo; group 2, candesartan; group 3, PD123319; group 4, PD123319 1 candesartan; group 5, HOE140;
group 6, HOE140 1 candesartan; group 7, indomethacin; group 8, indomethacin 1 candesartan.
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Discussion
In the present study, candesartan reduced infarct size, and
this beneficial effect was not related to favorable changes in
heart rate, LV peak pressure and blood flow. The infarct size
reduction by candesartan was abolished with blockade of
either the angiotensin II AT2-receptor or the bradykinin
B2-receptor or by cyclooxygenase inhibition, suggesting a car-
dioprotective action of candesartan through a signal cascade of
AT2-receptor activation, bradykinin and prostaglandins.
Critique of methods. Infarct size as determined by TTC-
staining after 90 min of ischemia and 2 h of reperfusion was
one major end point of the present study. Although the validity
of TTC-staining to identify myocardial necrosis within the time
frame of 90 min of ischemia and 2 h of reperfusion has not
been rigorously confirmed by electron microscopy, numerous
studies from different laboratories have used TTC-staining to
delineate myocardial necrosis within such time frame of isch-
emia/reperfusion (33,34).
Infarct size with PD123319 (group 3: 17 6 4%) and
HOE140 (group 5: 16 6 3%) was slightly—although not
significantly—less than with placebo (group 1: 22 6 5%). We
do not have any methodological or mechanistic explanation
other than that this slight reduction may be related to the
relatively small number of animals per group.
Pigs were used in the present study because their coronary
anatomy (18), extent of collateral flow (19) and time course of
infarct development most closely resemble that observed in
humans (20). In pigs, complete occlusion of the LAD coronary
artery results in a high incidence of ventricular fibrillation
(45% within 20 min) (35) and extensive infarction of the left
ventricle with subsequent pump failure. Therefore, in the
present study, the LAD perfusion territory was hypoperfused
at low but maintained flow, resulting in a large area at risk
(49% of the LV mass on the average), but a small infarct size
when expressed as a percent of the area at risk (22 6 5% in
group 1). However, infarct size expressed as a percent of the








WT (%) 1 42.4 6 6.3 21.5 6 0.9*# 1.4 6 2.3*
2 40.9 6 6.7 40.5 6 7.8 0.4 6 1.2*# 1.5 6 1.1*
3 40.0 6 3.3 39.6 6 3.0 0.1 6 1.0*# 0.2 6 0.8*
4 42.3 6 4.3 40.3 6 4.9 39.1 6 4.7 21.5 6 1.5*# 20.2 6 1.4*
5 36.0 6 4.5 28.8 6 3.4 1.2 6 1.3*# 2.0 6 0.9*
6 38.5 6 5.5 39.5 6 4.5 35.0 6 4.2 0.3 6 2.1*# 1.7 6 2.1*
7 36.5 6 3.1 27.8 6 2.6* 21.0 6 1.2*# 0.3 6 2.2*
8 40.2 6 4.5 31.0 6 5.6 29.3 6 4.5 21.6 6 1.6*# 0.0 6 1.9*
mTMF (mlzmin21zg21) 1 0.77 6 0.05 0.11 6 0.02*# 0.11 6 0.02*
2 0.81 6 0.04 0.87 6 0.09 0.16 6 0.01*# 0.16 6 0.02*
3 0.75 6 0.05 0.97 6 0.16 0.13 6 0.02*# 0.14 6 0.03*
4 0.86 6 0.06 1.01 6 0.11 1.08 6 0.11* 0.15 6 0.04*# 0.15 6 0.03*
5 0.71 6 0.07 0.77 6 0.06 0.12 6 0.01*# 0.13 6 0.01*
6 0.69 6 0.01 0.79 6 0.04* 0.09 6 0.02*# 0.12 6 0.03*
7 0.79 6 0.10 0.78 6 0.09 0.10 6 0.02*# 0.10 6 0.02*
8 0.76 6 0.04 0.75 6 0.04 0.81 6 0.06 0.14 6 0.03*# 0.16 6 0.04*
ENDO (mlzmin21zg21) 1 0.70 6 0.05 0.06 6 0.02*# 0.05 6 0.01*
2 0.92 6 0.08 0.89 6 0.10 0.05 6 0.02*# 0.06 6 0.02*
3 0.69 6 0.05 0.81 6 0.10 0.05 6 0.01*# 0.04 6 0.01*
4 0.74 6 0.04 0.92 6 0.11 0.91 6 0.08* 0.07 6 0.02*# 0.06 6 0.02*
5 0.70 6 0.07 0.87 6 0.10 0.05 6 0.01*# 0.06 6 0.01*
6 0.66 6 0.05 0.79 6 0.08 0.04 6 0.02*# 0.04 6 0.01*
7 0.89 6 0.13 0.86 6 0.13 0.05 6 0.01*# 0.04 6 0.01*
8 0.78 6 0.03 0.76 6 0.06 0.82 6 0.04 0.05 6 0.02*# 0.07 6 0.03*
MV˙ O2 (mlzmin
21zg21) 1 76.7 6 6.4 14.6 6 3.2*# 14.3 6 4.2*
2 78.0 6 5.5 73.9 6 8.8 18.7 6 2.0*# 18.3 6 2.5*
3 60.9 6 4.7 59.5 6 4.6 14.7 6 2.9*# 13.3 6 2.2*
4 70.3 6 5.2 78.6 6 8.2 77.2 6 6.4 16.8 6 4.3*# 15.9 6 4.2*
5 68.8 6 4.5 66.7 6 8.1 15.8 6 1.7*# 16.8 6 1.9*
6 66.9 6 2.1 62.6 6 2.4 11.0 6 2.4*# 10.4 6 3.0*
7 75.2 6 3.6 74.9 6 3.6 12.1 6 2.2*# 11.7 6 1.4*
8 74.2 6 4.5 75.5 6 4.9 78.1 6 6.6 16.2 6 4.4*# 17.1 6 3.9*
WT, anterior systolic wall thickening in percent of the end-diastolic wall thickness; mTMF, mean transmural
myocardial blood flow; ENDO, subendocardial blood flow; MV˙ O2, regional myocardial oxygen consumption; *p , 0.05
vs. control; #p , 0.05 vs. preceding value. Group 1, placebo group 2, candesartan; group 3, PD123319; group 4,
PD123319 1 candesartan; group 5, HOE; group 6, HOE 1 candesartan; group 7, indomethacin; group 8, indomethacin 1
candesartan.
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total LV mass in the present study averaged 11 6 3% in the
placebo group and was thus even somewhat higher than that in
a previous study using pigs with a total occlusion of only one
distal LAD branch (7%) (36).
Many patients suffering from coronary artery disease over
prolonged periods of time develop an extensive collateral
circulation (37). In this scenario, an acute total occlusion of
one coronary artery will result in low-flow rather than no-flow
ischemia in the dependent myocardium. Technically, perfusion
at low flow in the present study permitted the delivery of the
AT2-receptor antagonist PD123319 and the bradykinin B2-
receptor antagonist HOE140 throughout the sustained isch-
emia to maximize the local effect without influencing systemic
hemodynamics. Also, low-flow hypoperfusion allowed us to
relate infarct size to ischemic subendocardial blood flow.
Ischemic blood flow is, apart from the size of the area at risk,
the major determinant of infarct development (38), and there-
fore the relation of infarct size to subendocardial blood flow is
a more sensitive end point than infarct size per se.
In the present study, candesartan was used only at a single
dose of 1 mg/kg i.v. (25 to 40 mg total dose), which was derived
from studies in rats (39,40) and dogs (3,39). In patients with
hypertension, the prodrug candesartan cilexetil is given in oral
doses of 8 to 16 mg (41). This dose results in plasma concen-
trations of candesartan (21) comparable to those measured in
dogs with 1 mg/kg i.v. infusion of candesartan (39,42). Thus,
the dose of candesartan used in the present study appears to be
clinically relevant, as also reflected by a similar decrease in
systemic blood pressure (41).
AT1-receptor blockade and infarct size. When given 24 h
following the onset of ischemia in rat hearts, AT1-receptor-
blockade with losartan (43) and candesartan cilexetil (44), the
prodrug of candesartan, did not affect infarct size. Also,
pretreatment with losartan had no significant effect on infarct
size in rats (11–13) and rabbits (14–16). Pretreatment with
EXP3174, the active metabolite of losartan, did not limit
infarct size resulting from 90-min left circumflex coronary
artery (LCX) occlusion and 4-h reperfusion in anesthetized
dogs (17), whereas in pigs, EXP3174 reduced infarct size
resulting from 1-h LAD occlusion and 2 h reperfusion signif-
Figure 2. Effect of candesartan on infarct size. Infarct size in
percent of the area at risk was significantly reduced in the pigs
receiving candesartan (filled bars) as compared to that of the
placebo group (open bars) (p , 0.05 vs. placebo). In the
relationships between infarct size and subendocardial blood
flow, subendocardial blood flow in the area at risk correlated
inversely to infarct size in the placebo (open squares) and the
candesartan group (filled squares). Infarct size for any given
subendocardial blood flow was significantly reduced in the
candesartan group.
Figure 3. Effect of candesartan on infarct size during AT2-
receptor blockade. Infarct size in percent of the area at risk
was not different in the pigs receiving PD123319 1 candesar-
tan (filled bars) as compared to that of the PD123319 group
(open bars). The relationships between infarct size and sub-
endocardial blood flow between the two groups were superim-
posable.
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icantly from 71 6 13% to 35 6 17% (10). One possible
explanation for the difference between the two latter studies
may be the dosage of EXP3174, which was 0.1 mg/kg i.v. in
dogs (17) and 1 mg/kg i.v. in pigs (10). In the present study, the
active metabolite candesartan, also at a dose of 1 mg/kg i.v.,
reduced infarct size from 22 6 5% in placebo pigs to 10 6 3%
(p , 0.05, Fig. 2).
Candesartan and AT2-receptor activation. Cardiovascular
effects of angiotensin II (i.e., vasoconstriction and ventricular
hypertrophy), have been mainly attributed to AT1-receptor
activation (1), whereas the AT2-receptor mediates the inhibi-
tion of cell proliferation in rat coronary endothelial cells (45).
More than 80% of the angiotensin II receptors in both atrial
and LV preparations of the normal pig heart are AT1-
receptors (46). In human hearts, the predominant AT-receptor
subtype remains controversial. In membrane preparations
from normal human left ventricles, the ratio of AT1- to
AT2-receptors was either reported as 62%:38% (47) or as
29%:71% (48).
Results of the present study suggest that angiotensin II—in
the face of AT1-receptor blockade—exerts cardioprotective
effects via AT2-receptor activation (Fig. 3). One potential—
although purely speculative—explanation for the lack of an-
giotensin II to mediate cardioprotection without AT1-receptor
blockade would be that even elevated angiotensin II concen-
trations during ischemia (2) and following acute myocardial
infarction (49,50) may not be sufficient to activate enough
AT2-receptors. Indeed, PD123319 per se did not significantly
alter infarct size (Fig. 3), indicating that there was no signifi-
cant AT2-receptor mediated effect in the absence of AT1-
receptor blockade. In accordance with our findings, PD123319
had no effect on LV remodelling and function in rats with
myocardial infarction, but did abolish the beneficial effects on
LV remodelling achieved by the AT1-receptor antagonist
L-158809 (9). Only increased levels of angiotensin II in the
presence of an AT1-receptor antagonist (21), as well as the
redistribution of angiotensin II toward activation of AT2-
receptors, appear to induce cardioprotection.
Although PD123319 did not alter infarct size in the present
study, it has been reported to increase global LV function
Figure 4. Effect of candesartan on infarct size during bradyki-
nin B2-receptor blockade. Infarct size in percent of the area at
risk was not different in the pigs receiving HOE140 1 cande-
sartan (filled bars) as compared to that of the HOE140-group
(open bars). The relationships between infarct size and suben-
docardial blood flow between the two groups were superim-
posable.
Figure 5. Effect of candesartan on infarct size during cycloox-
ygenase inhibition. Infarct size in percent of the area at risk
was not different in the pigs receiving indomethacin 1 cande-
sartan (filled bars) as compared to that of the indomethacin
group (open bars). The relationships between infarct size and
subendocardial blood flow between the two groups were
superimposable.
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during reperfusion following 30-min global ischemia in isolated
rat hearts (51); this increase in contractile function during
reperfusion, may, however, reflect an AT1-receptor-mediated
positive inotropic effect (52) after redistribution of angiotensin
II toward activation of AT1-receptors.
Candesartan and bradykinin. In isolated dog coronary
arteries, AT2-receptor activation induces the activation of a
local kallikrein-kinin system and generation of bradykinin (22).
The protective effects of AT1-receptor blockade on ventricular
fibrillation in isolated ischemic rat hearts are abolished by
blockade of the bradykinin B2-receptor (7). Also, in rats with
heart failure secondary to myocardial infarction, the beneficial
effects of AT1-receptor blockade on LV remodelling and
function are abolished by the B2-receptor antagonist HOE140
(9). In accordance, in the present study, the infarct size-
limiting effect of candesartan was also abolished by pretreat-
ment with the bradykinin B2-receptor antagonist HOE140
(Fig. 4). Interestingly, the beneficial effects of ACE-inhibitors
on infarct size in rats (11), rabbits (53) and dogs (2) and on
myocardial stunning in dogs (25) are also mediated by brady-
kinin.
Candesartan and prostaglandins. The AT1-receptor an-
tagonist losartan induces prostacyclin release in porcine aortic
smooth muscle cells (54). In accordance, in the present study,
the infarct size-limiting effect of candesartan was also abol-
ished by pretreatment with the cyclooxygenase inhibitor indo-
methacin (Fig. 5), suggesting that prostaglandins mediate the
cardioprotection afforded by AT1-receptor blockade. Indeed,
stimulation of endogenous prostacyclin release reduces infarct
size (55) and improves the contractile recovery from myocar-
dial stunning (56) in pigs. Also, the beneficial effects of the
ACE-inhibitor ramiprilat on infarct size in rats (11) and on
myocardial stunning in dogs (25) are mediated by prostaglan-
dins.
Clinical implications. In patients with myocardial infarc-
tion, cardioprotective effects of ACE-inhibitors have been
documented in large clinical trials (57,58). However, some
patients discontinue therapy with ACE-inhibitors because of
adverse experiences, whereas AT1-receptor antagonists appear
to be better tolerated (59). When added to the preexisting
treatment of heart failure in patients, AT1-receptor blockade
decreases mortality to a greater extent than does additional
ACE-inhibitor treatment (59). Moreover, combined ACE-
inhibition and AT1-receptor antagonism may act in an additive
manner to reduce systemic vascular resistance in humans (60)
and improve LV function in pigs with chronic heart failure
(46).
With reference to the infarct size reduction by candesartan
observed in the present study, patients under treatment with
AT1-receptor blocker for indications such as hypertension and
ventricular remodelling after myocardial infarction are likely
to have improved prognosis when suffering an acute myocar-
dial infarction.
Conclusions. In the present study, the angiotensin II AT1-
receptor antagonist candesartan exerted a cardioprotective
action that was not related to more favorable systemic hemo-
dynamics or regional myocardial blood flow, but was mediated
through a signal cascade of AT2-receptor activation, bradyki-
nin and prostaglandins.
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